Diagnostics Partnering Terms and Agreements -





Published: January 2014 | Edition: 6th Pages: 3,696 (including appendices)

The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

                             

Chapter 3 provides a review of the leading diagnostics deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech and and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies where diagnostic deals are announced with a brief summary, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2007. The chapter is organized by specific diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2007.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.

 

Report scope 

 

Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.

 

Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in diagnostic dealmaking in the biopharma industry since 2007
  • Analysis of diagnostic deal structure
  • Case studies of real-life diagnostic deals
  • Access to over 3,700 diagnostic deals
  • The leading diagnostic deals by value since 2007
  • Most active diagnostic dealmakers since 2007
  • The leading diagnostic partnering resources

 

In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:

 

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Executive Summary 

Chapter 1 – Introduction 

Chapter 2 – Trends in diagnostic dealmaking 

 

2.1. Introduction

2.2. Diagnostic partnering over the years

2.3. Most active diagnostic dealmakers

2.4. Big pharma diagnostic dealmaking activity

2.5. Big biotech diagnostic dealmaking activity

2.6. Diagnostics partnering by deal type

2.7. Diagnostics partnering by stage of development

2.8. Diagnostics partnering by disease type

2.9. Diagnostics partnering by specific technology type

2.10. Average deal terms for diagnostics partnering

2.10.1 Diagnostic partnering headline values

2.10.2 Diagnostic deal upfront payments

2.10.3 Diagnostic deal milestone payments

2.10.4 Diagnostic royalty rates

2.11. The anatomy of diagnostic partnering

2.11.1. The anatomy of a diagnostic deal

2.11.1.a. Case study 1: Sequenom – Lenetex – January 2007

2.11.1.b. Case study 2: Celera – Siemens Medical Solutions – July 2007

2.11.1.c. Case study 3: Salix Pharmaceuticals – Photocure – 2010

 

Chapter 3 – Leading diagnostic deals 

 

3.1. Introduction

3.2. Top diagnostic deals by value

3.3. Top diagnostic deals involving big pharma

3.4. Top diagnostic deals involving big biotech

 

Chapter 4 – Big pharma diagnostic deals 

 

4.1. Introduction

4.2. How to use bigpharma diagnostic partnering deals

4.3. Big pharma partnering company profiles

Abbott

Actavis

Amgen

Astellas

AstraZeneca

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Fresenius

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Mylan

Novartis

Otsuka

Pfizer

Purdue

Roche

Sanofi

Servier

Takeda

Teva

UCB

 

Chapter 5 – Big biotech diagnostic deals 

 

5.1. Introduction

5.2. How to use big biotech diagnostic partnering deals

5.3. Big biotech partnering company profiles

Abbott

Array Biopharma

Biocon

Biomarin Pharmaceuticals

Elan

Enzo Biochem

Genmab

Ipsen

Isis Pharmaceuticals

Morphosys

Regeneron Pharmaceuticals

Seattle Genetics

Swedish Orphan Biovitrum

UCB

 

Chapter – Diagnostics dealmaking directory 

 

6.1. Introduction

6.2. By stage of development

Discovery

Marketed

Phase I

Phase II

Phase III

Preclinical

6.3. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

6.4. By therapy area

Cardiovascular

Central Nervous System

Dental

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Gynaecology

Hematology

Hospital care

Infectives

Metabolic

Musculoskeletal

Obstetrics

Oncology

Pediatrics

Respiratory

 

Chapter 7 – Diagnostics dealmaking by technology type 

 

7.1. Introduction

7.2. Deals by diagnostics type

Diagnostics

 

Chapter 8 – Diagnostic partnering resource center 

 

8.1. Online diagnostic partnering

8.2. Diagnostic partnering events

8.3. Further reading on diagnostic dealmaking

 

Appendices 

Appendix 1 – Deal type definitions

Recent report titles from CurrentPartnering

 

 

Table of figures 

 

Figure 1: Diagnostic partnering since 2007

Figure 2: Most active diagnostic dealmakers 2007-2013

Figure 3: Bigpharma – top 50 – diagnostic deals 2007 to 2013

Figure 4: Big pharma diagnostic deal frequency – 2007 to 2013

Figure 5: Big biotech – top 50 – diagnostic deals 2007 to 2013

Figure 6: Big biotech diagnostic deal frequency – 2007 to 2013

Figure 5: Diagnostics partnering by deal type since 2007

Figure 6: Diagnostics partnering by stage of development since 2007

Figure 7: Diagnostics partnering by disease type since 2007

Figure 8: Diagnostics partnering by oncology target since 2007

Figure 10: Diagnostics partnering by diagnostics type since 2007

Figure 9: Diagnostic deals with a headline value – by stage of development

Figure 10: Diagnostic deal headline value distribution – discovery stage, US$million

Figure 11: Diagnostic deal headline value distribution – preclinical stage, US$million - detail

Figure 12: Diagnostic deal headline value distribution – phase I stage, US$million

Figure 13: Diagnostic deal headline value distribution – phase II stage, US$million

Figure 14: Diagnostic deal headline value distribution – phase III stage, US$million

Figure 15: Diagnostic deal headline value distribution –regulatory stage, US$million

Figure 16: Diagnostic deal headline value distribution – marketed stage, US$million

Figure 17: Summary median headline value by stage of development, 2007-2013

Figure 18: Diagnostic deals with upfront payment values – by stage of development

Figure 19: Diagnostic deal upfront payment distribution – discovery stage, US$million

Figure 20: Diagnostic deal upfront payment distribution – preclinical stage, US$million

Figure 21: Diagnostic deal upfront payment distribution – phase I stage, US$million

Figure 22: Diagnostic deal upfront payment distribution – phase II stage, US$million

Figure 23: Diagnostic deal upfront payment distribution – phase III stage, US$million

Figure 24: Diagnostic deal upfront payment distribution – regulatory stage, US$million

Figure 25: Diagnostic deal upfront payment distribution – marketed stage, US$million

Figure 26: Summary median headline value by stage of development, 2007-2013

Figure 27: Diagnostic deals with milestone payment values – by stage of development

Figure 28: Diagnostic deal milestone payment distribution – discovery stage, US$million

Figure 29: Diagnostic deal milestone payment distribution – preclinical stage, US$million

Figure 30: Diagnostic deal milestone payment distribution – phase I stage, US$million

Figure 31: Diagnostic deal milestone payment distribution – phase II stage, US$million

Figure 32: Diagnostic deal milestone payment distribution – phase III stage, US$million

Figure 33: Diagnostic deal milestone payment distribution – regulatory stage, US$million

Figure 34: Diagnostic deal milestone payment distribution – marketed stage, US$million

Figure 35: Diagnostic deals with royalty rates

Figure 36: Diagnostic deal rolyalty rate payment distribution – discovery stage, US$million

Figure 37: Diagnostic deal royalty rate payment distribution – preclinical stage, US$million

Figure 38: Diagnostic deal royalty rate payment distribution – phase I stage, US$million

Figure 39: Diagnostic deal royalty rate payment distribution – phase II stage, US$million

Figure 40: Diagnostic deal royalty rate payment distribution – phase III stage, US$million

Figure 41: Diagnostic deal royalty rate payment distribution – regulatory stage, US$million

Figure 42: Diagnostic deal royalty rate payment distribution – marketed stage, US$million

Figure 43: Summary median headline value by stage of development, 2007-2013

Figure 44: Components of the typical diagnostic deal structure

Figure 47: Top diagnostic deals by value since 2007

Figure 46: Top diagnostic deals signed by big pharma value since 2007

Figure 50: Top diagnostic deals signed by big biotech value since 2007

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events

Figure 49: Deal type definitions

Appendices 

 

Appendix A

1. By Company A-Z

Appendix B

1. By stage of development

2. By deal type

3. By therapy area